A Phase 3 interventional study of ELX/TEZ/IVA and IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 21 sites in 5 countries. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2025-05-18.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing elexacaftor in Cystic Fibrosis — 2 open to participants now, 5 under way, 2 of them phase 3. elexacaftor · Cystic Fibrosis.
Among the 23 studies testing elexacaftor in Cystic Fibrosis, this one is the 21st largest by enrollment, is one of 5 that started in 2020, is one of 19 in phase 3, and was the 8th registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →2 of the 23 studies testing elexacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:
Istituto Giannina Gaslini · Sites in Italy
Ages 6+
Arkansas Children's Hospital Research Institute · Sites in United States
Ages 3+
By country, each count listing its studies:
elexacaftor: first FDA approval 2019 (TRIKAFTA (COPACKAGED)), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 6 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 5 started in 2020.
This study's enrollment of 64 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 120 across the 23 interventional studies. Of the 18 that completed or were terminated, 17 (94%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 23 have an industry lead sponsor. The 4 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated: 3 open now, 8 under way, 5 of them phase 3. Of 112 finished, 80 (71%) have results posted.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 68th largest by enrollment of the 116 interventional ones that give a count, is one of 5 that started in 2020, is one of 62 in phase 3, and was the 91st registered.
Vertex Pharmaceuticals Incorporated’s Cystic Fibrosis studies by the year they started, since 2007.
2 of the studies testing elexacaftor in Cystic Fibrosis that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05331183Phase 3Vertex Pharmaceuticals IncorporatedStudy to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del | 2027-04-06 |
| NCT06460506Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 23 studies testing elexacaftor in Cystic Fibrosis, from their registry updates:
Among Vertex Pharmaceuticals Incorporated’s 125 in Cystic Fibrosis:
This tab as a report to print or save as PDF → With an account.
The study evaluates the long-term safety, tolerability, efficacy, and pharmacodynamics of elexacaftor (ELX, VX-445) in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in participants with cystic fibrosis (CF).
Key Inclusion Criteria:
Key Exclusion Criteria:
Other protocol defined Inclusion/Exclusion criteria may apply.
Participants greater than or equal to (≥) 6 years and less than (\<) 12 years of age and weighing \<30 kilograms (kg) received ELX (elexacaftor) 100 milligram (mg) once daily (qd) /TEZ (tezacaftor) 50 mg qd/IVA (ivacaftor) 75 mg every 12 hours (q12h) and those weighing (≥) 30 kg received ELX 200 mg qd/TEZ 100 mg qd/IVA 150 mg in the treatment period for up to 192 weeks. Participants ≥12 years of age received ELX 200 mg qd/ TEZ 100 mg qd/IVA 150 mg q12h in the treatment period for up to 192 weeks.
Drug: ELX/TEZ/IVA · Drug: IVA
Drug pages: Elexacaftor · Tezacaftor · Ivacaftor
Fixed-dose combination (FDC) tablet for oral administration
Also known as: VX-445/VX-661/VX-770, elexacaftor/tezacaftor/ivacaftor
Mono tablet for oral administration.
Also known as: VX-770, ivacaftor
Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame: From Baseline up to Week 196
Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
Time frame: From Baseline up to Week 192
Absolute Change in Sweat Chloride (SwCl)
Sweat samples were collected using an approved collection device.
Time frame: From Baseline up to Week 192
Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
Time frame: From Baseline up to Week 192
Absolute Change in Body Mass Index (BMI)
BMI was defined as weight in kg divided by squared height in meters (m\^2).
Time frame: From Baseline up to Week 192
Absolute Change in BMI-for-age Z-score
BMI was defined as weight in kg divided by squared height in meters (m\^2). The z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean.
Time frame: From Baseline up to Week 192
Number of Participants With Pulmonary Exacerbations (PEx) for 106/107
Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.
Time frame: From Baseline up to Week 192
Number of CF-related Hospitalizations for 106/107
The total number of CF related hospitalization (Planned + Unplanned) events across all participants were reported.
Time frame: From Baseline up to Week 192
Absolute Change in Lung Clearance Index 2.5 (LCI 2.5)
The LCI2.5 index is the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting values and is calculated by dividing the sum of exhaled tidal breaths (cumulative exhaled volume (CEV)) by simultaneously measured functional residual capacity (FRC). An LCI of 7.5 and below is normal; values greater than 7.5 are abnormal. LCI is able to detect abnormalities in lung function earlier than more traditional modalities such as spirometry.
Time frame: From Baseline up to Week 192
Absolute Change in Weight
Time frame: From Baseline up to Week 192
Absolute Change in Weight-for-age Z-score
The z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean.
Time frame: From Baseline up to Week 192
Absolute Change in Height
Time frame: From Baseline up to Week 192
Absolute Change in Height-for-age Z-score
The z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean.
Time frame: From Baseline up to Week 192
The study was conducted in two parts, Part A and Part B. Participants of both Parts A and B received the same treatment (ELX,TEZ,IVA). Therefore, results data were planned to be collected and analyzed for the overall population of the study and not for separate parts.
| Milestone | ELX/TEZ/IVA | Additional Participants for Cumulative Triple Combination (TC) Efficacy Set |
|---|---|---|
| Started | 64 | 2 |
| Part a completed | 60 | 0 |
| Rollover to part b | 48 | 0 |
| Cumulative tc efficacy set 106/107 | 64 | 2 |
| Completed | 39 | 0 |
| Not completed | 25 | 2 |
| Withdrew: Participants did not rollover to part b | 12 | 0 |
| Withdrew: Withdrawal of consent (not due to ae) | 6 | 0 |
| Withdrew: Commercial drug is available for participant | 6 | 0 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Not enrolled in 107 study | 0 | 2 |
| Participants | ELX/TEZ/IVA |
|---|---|
| Participants with TEAEs | 64 |
| Participants with SAEs | 7 |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
| percent predicted FEV1 | ELX/TEZ/IVA |
|---|---|
| Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) | 9.6 (5.4 to 13.7) |
Sweat samples were collected using an approved collection device.
| millimole per liter (mmol/L) | ELX/TEZ/IVA |
|---|---|
| Absolute Change in Sweat Chloride (SwCl) | -57.9 (-63.3 to -52.5) |
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
| units on a scale | ELX/TEZ/IVA |
|---|---|
| Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score | 10.0 (6.9 to 13.0) |
BMI was defined as weight in kg divided by squared height in meters (m\^2).
| kg/m^2 | ELX/TEZ/IVA |
|---|---|
| Absolute Change in Body Mass Index (BMI) | 3.60 (2.98 to 4.23) |
BMI was defined as weight in kg divided by squared height in meters (m\^2). The z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean.
| z-score | ELX/TEZ/IVA |
|---|---|
| Absolute Change in BMI-for-age Z-score | 0.39 (0.19 to 0.59) |
Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.
| Participants | ELX/TEZ/IVA |
|---|---|
| Number of Participants With Pulmonary Exacerbations (PEx) for 106/107 | 9 |
The total number of CF related hospitalization (Planned + Unplanned) events across all participants were reported.
| hospitalizations | ELX/TEZ/IVA |
|---|---|
| Number of CF-related Hospitalizations for 106/107 | 5 |
The LCI2.5 index is the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting values and is calculated by dividing the sum of exhaled tidal breaths (cumulative exhaled volume (CEV)) by simultaneously measured functional residual capacity (FRC). An LCI of 7.5 and below is normal; values greater than 7.5 are abnormal. LCI is able to detect abnormalities in lung function earlier than more traditional modalities such as spirometry.
| index | ELX/TEZ/IVA |
|---|---|
| Absolute Change in Lung Clearance Index 2.5 (LCI 2.5) | -2.33 (-2.87 to -1.79) |
| Kilogram (kg) | ELX/TEZ/IVA |
|---|---|
| Absolute Change in Weight | 19.9 (18.1 to 21.7) |
The z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean.
| z-score | ELX/TEZ/IVA |
|---|---|
| Absolute Change in Weight-for-age Z-score | 0.38 (0.20 to 0.55) |
| centimeters (cm) | ELX/TEZ/IVA |
|---|---|
| Absolute Change in Height | 23.1 (21.6 to 24.6) |
The z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean.
| z-score | ELX/TEZ/IVA |
|---|---|
| Absolute Change in Height-for-age Z-score | 0.04 (-0.12 to 0.19) |
Collected over Day 1 Up to Week 196. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ELX/TEZ/IVA | 0/64 (0%) | 7/64 (10.9%) | 62/64 (96.9%) |
| Event | ELX/TEZ/IVA |
|---|---|
| ConstipationGastrointestinal disorders | 3/64 |
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 2/64 |
| PyrexiaGeneral disorders | 1/64 |
| Anaphylactic reactionImmune system disorders | 1/64 |
| Haematuria traumaticInjury, poisoning and procedural complications | 1/64 |
| Idiopathic intracranial hypertensionNervous system disorders | 1/64 |
| Event | ELX/TEZ/IVA |
|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 40/64 |
| PyrexiaGeneral disorders | 28/64 |
| HeadacheNervous system disorders | 26/64 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 24/64 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 23/64 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 21/64 |
| Upper respiratory tract infectionInfections and infestations | 19/64 |
| COVID-19Infections and infestations | 18/64 |
| VomitingGastrointestinal disorders | 17/64 |
| Abdominal painGastrointestinal disorders | 14/64 |
All participants who received at least one dose of the study drug in this OLE study were included in the baseline characteristics.
| Age, Continuous(years) | ELX/TEZ/IVA |
|---|---|
| Mean | 9.3 ± 1.8 |
| Sex: Female, Male(Participants) | ELX/TEZ/IVA |
|---|---|
| Female | 39 |
| Male | 25 |
| Race/Ethnicity, Customized(Participants) | ELX/TEZ/IVA |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 56 |
| Not collected per local regulations | 8 |
| Race/Ethnicity, Customized(Participants) | ELX/TEZ/IVA |
|---|---|
| White | 55 |
| Asian | 0 |
| Not collected per local regulations | 8 |
| More than one Race | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent research/clinical-trial-data-sharing
Ran from Feb 2020 to primary completion in Feb 2024, 48 months.
Results were first posted in May 2025, 1 year 2 months after primary completion.
Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 48 months is above that.
Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Elexacaftor · Tezacaftor · Ivacaftor
Vertex Pharmaceuticals Incorporated →